Loading
Brainstorm Cell Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lebovits Chaim, was filed 02 Oct 2024.
Insider Decl.
113
Thresholds
n/a
Buy Volume
€700,588
11 ops. · all time
Sell Volume
€909,696
7 ops. · all time
Since the insiders bought
- -69.6%Entry US$2.37 · Close at T+365 US$0.72
- -80.8%Entry US$21.90 · Close at T+365 US$4.20
- -77.6%Entry US$218.70 · Close at T+365 US$49.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.80
Analyst consensus
3.00/5
Income statement
EBITDA-US$9.8M
Net income-US$10.3M0.0% margin
Valuation
PER (forward)-0.8x
Beta0.26
Balance sheet & cash
Market capUS$8.8M
Total debtUS$208k
Free Cash Flow-US$7M
Profitability & ownership
ROA-370.8%
% insiders8.7%
% institutions0.0%
Last declaration on 28 July 2026
Declarations113 total
100,000 shares0Common StockSEC:0001104659-26-087588:0
120,000 shares0Common StockSEC:0001104659-26-068335:0
200,000 shares0Common StockSEC:0001104659-26-068336:0
100,000 shares0Common StockSEC:0001104659-26-068337:0
150,000 shares0Common StockSEC:0001104659-26-068338:0
1,800,000 shares0Common StockSEC:0001104659-26-068339:0
50,000 shares0Common StockSEC:0001104659-25-001674:0
20,000 shares0Common StockSEC:0001104659-25-000892:1
40,000 shares0Common StockSEC:0001104659-25-000892:0
50,000 shares0Common StockSEC:0001104659-25-000888:0
40,000 shares0Common StockSEC:0001104659-25-000894:0
24,000 shares0Common StockSEC:0001104659-25-000887:0
20,000 shares0Common StockSEC:0001104659-25-000889:0
24,000 shares0Common StockSEC:0001104659-25-000893:0
40,000 shares0Common StockSEC:0001104659-25-000891:0
120,000 shares0Common StockSEC:0001104659-25-000895:0
30,666 shares0Common StockSEC:0001104659-25-000890:0
30,666 shares0Common StockSEC:0001104659-25-000885:0
1,836 shares@ US$3.42722.2% of flowCommon StockSEC:0001104659-24-105215:1
Canonical exit: 30 Dec 2024 (T+90)
22,000 shares@ US$0.2282.5% of flowCommon StockSEC:0001104659-24-105215:0
Canonical exit: 29 Dec 2024 (T+90)
63,000 shares@ US$0.3503100.0% of flowCommon StockSEC:0001104659-24-082328:0
30,000 shares0Common StockSEC:0001104659-24-074873:0
15,000 shares@ US$0.51834.0% of flowCommon StockSEC:0001104659-24-067529:0
25,000 shares@ US$0.645.6% of flowCommon StockSEC:0001104659-24-064415:1
25,000 shares@ US$0.5797.5% of flowCommon StockSEC:0001104659-24-064415:0
25 of 113 declarations
About Brainstorm Cell Therapeutics Inc.
Sankesh Abbhi, Director of Brainstorm Cell Therapeutics Inc., made the largest purchase on file, EUR 532,232 on July 15, 2020, and David Setboun, EVP and COO, bought for EUR 56,838 on July 16, 2020. During the same week, ACC International Holdings Ltd. sold for EUR 476,665 on July 13, 2020, EUR 211,787 on July 15 and EUR 92,499 on July 16, 2020, the three largest sales. The 7 sales are worth EUR 909,696 (median EUR 44,136), against 11 purchases worth EUR 700,588 (median EUR 10,492): 61% of open-market trades are purchases. Preetam Shah, EVP, CFO and Treasurer, signs 24 of the 113 filings, including 2 purchases, with EUR 41,407 on December 24, 2019. Anthony J. Polverino, Director, has 11 with no purchase or sale, Ralph Dr. Kern, COO and Chief Medical Officer, 8, and Uri Yablonka, EVP & Chief Business Officer, 7. On December 24, 2019, 3 insiders bought for EUR 62,445. Filings from 24 filers were published between June 23, 2016 and July 28, 2026, with a peak of 19 in 2024 and 91 grants, a median of 2 days after the trade. The 6 filings of the last twelve months contain no purchase or sale. The US healthcare and pharma company is worth USD 8.8 million, with 8.7% held by insiders.
